Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Bacterial infection and inflammatory responses
- The first step of activation
- Pattern recognition receptors
- The TLR family
- Toll molecular structure
- MyD88
- The signalling pathways of Toll and TLR4
- Components of the signaling pathway
- NFkB as a central regulator
- NFkB transcription in mammals
- Ub modifications and their cellular functions
- MAP kinase signaling pathways
- LPS signaling pathways in human monocytes
- TRAF3 and the signaling complex
- Cytokines in TRAF3 deficient macrophages
- The entire INF response is TRAF3 dependent
- The TRAF3 signaling pathway
- Negative regulation of TLR signaling
- Pattern recognition receptors (2)
- TNFalpha induced apoptosis
- The TRAF family
- CD40 signaling and its functions in B cells
- The role of TRAFs in MAP kinase activation
- Roles of TRAF proteins in CD40 signaling
- Ubc13 E2 ubiquitin-conjugating enzyme
- MEKK1 activation
- CD40 complex assembly
- CD40 complex release to cytosol
- c-IAP1 and c-IAP2
- The role of c-IAP1 and c-IAP2 in complex release
- c-IAP2 target
- Polyubiquitination of TRAF2 and TRAF3
- c-IAP proteosome activity
- A model for TNF MAP kinase activation
- Why delay MAP kinase activity
- IKKalpha dependent alternative pathway
- Activation of IKKalpha by NIK
- TRAF3 recruits TRAF2 and c-IAPs to NIK
- cIAP1/2 regulate TRAF3 degradation
- The E3 ligase activity of c-IAP2
- A model for the alternative NFkB activation
- Pattern recognition receptors (3)
- The NLR Family
- Pathogen-associated receptors
- The inflammasomes and caspase-1
- Mechanism of action of NALP3
- Structure of the inflammasomes
- NFkB as a negative regulator of the inflammasome
- Regulation of IL-1beta production
- NFkB activation in macrophages and neutrophiles
- IL-1beta as an alternative immune response
- IL-1beta response to LT is dependent
- Summary
Topics Covered
- Understanding how receptors involved in the detection of infection (TLRs and NLRs) and inflammation (TNFRs) mediated their biological effects
- The activation of innate immune responses depends on recognition of infectious organisms (bacteria, fungi, viruses, etc.) by specialized pattern recognition receptors that include the large families of membrane-associated TLRs and cytosolic NLRs
- Signaling mechanisms used by TLRs and NLRs, as well as by TNFRs that respond to pro-inflammatory cytokines
- Their biological effects include the production of cytokines, chemokines, anti-microbial peptides and enzymes that generate inflammatory mediators and reactive oxygen
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Karin, M. (2009, May 31). Signaling by innate immune receptors [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 21, 2024, from https://doi.org/10.69645/GCIX3503.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Michael Karin has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.